Ces Urol 2021, 25(4):236-243 | DOI: 10.48095/cccu2021037

Serum oncomarkers for prostate cancer

Jakub Řezáč, Otakar Čapoun, Viktor Soukup

Urologická klinika VFN a 1. LF UK v Praze

Řezáč J, Čapoun O, Soukup V. Serum oncomarkers for prostate cancer. Prostate cancer (PC) is one of the most diagnosed oncological diseases. An integral part of the diagnostic process is detection of oncomarkers, which we measure in blood serum, urine, or tissue samples. In clinical practice, we most often utilize serum oncomarkers, especially Prostate Specific Antigen (PSA) or its derivatives free PSA, PSA Doubling Time, PSA Velocity and PSA Density. To make the indication of a prostate biopsy more accurate, we can use other tests, such as Prostate Health Index (PHI). Another commercially available alternative is Four-kallikrein Panel (4K). Among the latest markers, we list, in the United States already approved, Circulating Tumor Cells (CTC), as well as for now experimental microRNA (miRNA). The aim of this article is to show a brief overview of currently used and experimental serum oncomarkers of PC.

Keywords: Oncomarkers, biomarkers, prostate cancer.

Received: September 7, 2021; Revised: November 1, 2021; Accepted: November 15, 2021; Prepublished online: November 1, 2021; Published: December 13, 2021